Denosumab biosimilar by Lupin for Post Menopausal Osteoporosis: Likelihood of Approval

Denosumab biosimilar is under clinical development by Lupin and currently in Phase III for Post Menopausal Osteoporosis.

Risk adjusted net present value: What is the current valuation of Atossa Therapeutics’s Endoxifen? – Pharmaceutical Technology

Share this article The revenue for Endoxifen is expected to reach an annual total of $58 mn by 2035 globally based off GlobalData’s Expiry Model.

December 5, 2023

AstraZeneca CEO calls opening IRA drug price offer ‘relatively encouraging’ in first characterization of talks

The government’s first offer to AstraZeneca under the IRA’s drug price negotiations that began this month is “relatively encouraging,” CEO Pascal Soriot said Thursday, at

February 9, 2024

Elation Health Unveils Unified EHR and Billing Solution for Primary Care

What You Should Know: Elation Health, the clinical-first technology company powering innovation in primary care, today announced general availability of the industry’s first unified EHR

October 4, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.